Scilex Holding (SCLX) Metrics: History & Chart

Scilex Holding Company(SCLX)

Drug Manufacturers - General · Palo Alto, CA

$3.96+0.14 (+3.66%)

Delayed quote: Oct 6, 2026, 3:44 PM EDT

About Scilex Holding Company

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Palo Alto, CA

34 employees

www.scilexholding.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Henry H. Ji

View full financials

Third-Party DCF Estimate (FMP)	N/A
Price Gap vs Third-Party Estimate	N/A

7D Total Return	-14.92%
30D Total Return	-29.52%
YTD Total Return	-68.69%
1Y Total Return	-75.79%
3Y Total Return	-92.63%
5Y Total Return	-98.91%
10Y Total Return	N/A
15Y Total Return	N/A
20Y Total Return	N/A

2026	-68.69%
2025	-18.23%
2024	-79.10%
2023	-48.87%
2022	-60.26%
2021	N/A
2020

CAGR TTM	-75.63%
CAGR 3Y	-58.06%
CAGR 5Y	-59.50%
CAGR 10Y	N/A
CAGR 15Y	N/A
CAGR 20Y	N/A

PE Ratio	N/A
PE Ratio Avg TTM	N/A
PE Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

All Metrics

SCLX Valuation Metrics

SCLX Stock Price Metrics

SCLX Dividend Metrics

SCLX Growth Rate Metrics

SCLX Discounted Cash Flow Metrics

SCLX Returns By Period

SCLX Yearly Returns

SCLX Average Annual Returns By Period (CAGR)

SCLX Revenue Metrics

SCLX PE Ratio Metrics

SCLX PS Ratio Metrics

SCLX PB Ratio Metrics

SCLX Price to Free Cash Flow Ratio Metrics

SCLX Debt to Equity Ratio Metrics

SCLX PEG Ratio Metrics

SCLX FCF Yield

SCLX Earnings Yield

SCLX EBITDA Yield

SCLX OCF Yield

SCLX EV/EBIT Ratio Metrics

SCLX EV/EBITDA Ratio Metrics

SCLX EV/Assets Ratio Metrics

SCLX EV/Sales Ratio Metrics

SCLX Current Ratio Metrics

SCLX Quick Ratio Metrics

SCLX ROIC Metrics

SCLX Return on Assets Metrics

SCLX Return on Equity Metrics

SCLX Net Profit Margin Metrics

SCLX Gross Profit Margin Metrics

SCLX Tax Rate Metrics

PS Ratio	0.83
PS Ratio Avg TTM	1.73
PS Ratio Avg 3Y	2.42
Current VS TTM Avg	-52.09%
Current VS 3Y Avg	-65.70%
Current VS 5Y Avg	-94.80%

PB Ratio	19.17
PB Ratio Avg TTM	53.08
PB Ratio Avg 3Y	188.78
Current VS TTM Avg	-63.88%
Current VS 3Y Avg	-89.85%
Current VS 5Y Avg	-89.85%

PFCF Ratio	9.16
PFCF Ratio Avg TTM	4.54
PFCF Ratio Avg 3Y	5.34
Current VS TTM Avg	+101.82%
Current VS 3Y Avg	+71.52%
Current VS 5Y Avg	+71.52%

Debt/Equity Ratio	(0.31)
Debt/Equity Ratio Avg TTM	(0.38)
Debt/Equity Ratio Avg 3Y	(0.45)
Current VS TTM Avg	+19.49%
Current VS 3Y Avg	+31.13%
Current VS 5Y Avg	+27.54%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	10.91%
FCF Yield Avg TTM	25.34%
FCF Yield Avg 3Y	24.30%
Current VS TTM Avg	-56.95%
Current VS 3Y Avg	-55.11%
Current VS 5Y Avg	-55.11%

Earnings Yield	N/A
Earnings Yield Avg TTM	N/A
Earnings Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.48
Ev/Assets Ratio Avg TTM	0.51
Ev/Assets Ratio Avg 3Y	1.89
Current VS TTM Avg	-5.34%
Current VS 3Y Avg	-74.56%
Current VS 5Y Avg	-92.68%

Ev/Sales Ratio	3.84
Ev/Sales Ratio Avg TTM	4.06
Ev/Sales Ratio Avg 3Y	4.50
Current VS TTM Avg	-5.34%
Current VS 3Y Avg	-14.59%
Current VS 5Y Avg	-78.96%

Current Ratio	0.07
Current Ratio Avg TTM	0.08
Current Ratio Avg 3Y	0.12
Current VS TTM Avg	-9.24%
Current VS 3Y Avg	-41.07%
Current VS 5Y Avg	-54.60%

Quick Ratio	0.06
Quick Ratio Avg TTM	0.07
Quick Ratio Avg 3Y	0.11
Current VS TTM Avg	-10.92%
Current VS 3Y Avg	-42.81%
Current VS 5Y Avg	-50.04%

ROIC	N/A
ROIC Avg 3Y	(279.88%)
ROIC Avg 5Y	(393.29%)
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A

ROA	(176.33%)
ROA Avg TTM	(52.91%)
ROA Avg 3Y	(23.81%)
Current VS TTM Avg	-233.24%
Current VS 3Y Avg	-640.62%
Current VS 5Y Avg	-746.74%

ROE	N/A
ROE Avg TTM	(328.95%)
ROE Avg 3Y	(186.33%)
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Net Profit Margin	(1414.57%)
Net Profit Margin Avg TTM	(1196.80%)
Net Profit Margin Avg 3Y	(348.48%)
Current VS TTM Avg	-18.20%
Current VS 3Y Avg	-305.92%
Current VS 5Y Avg	-410.64%

Gross Profit Margin	49.68%
Gross Pft Margin Avg TTM	42.17%
Gross Pft Margin Avg 3Y	66.22%
Current VS TTM Avg	+17.81%
Current VS 3Y Avg	-24.98%
Current VS 5Y Avg	-30.39%

Tax Rate	(0.05%)
Tax Rate Avg 3Y	N/A
Tax Rate Avg 5Y	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A
Current VS 10Y Avg	N/A